Atrial fibrillation (AF)

Diagnostic and therapeutic approach

Dronedarone (Multaq)



No loading dose


2x400 mg/day


  • Hypersensitivity to the active substance or to any of the excipients.
  • AV block of 2nd or 3rd degree, bundle branch block, atrial conduction defects and sinus disease.
  • Unstable hemodynamic conditions.
  • Heart failure.
  • Systolic dysfunction of the left ventricle.
  • Interstitial lung disease.
  • History of liver or lung disease under treatment with amiodarone.
  • Co-administration of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, ritonavir and cyclosporine (see "Interactions").
  • Drugs inducing torsades de pointes such as phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides such as erythromycin, Class I and III antiarrhythmics (see "Interactions").
  • QTc interval (Bazett) ≥500 msec.
  • Severe hepatic impairment.
  • Pregnancy, lactation.